Azurity Pharmaceuticals, Inc. (Azurity) announced the closing of its acquisition of Slayback Pharma LLC (Slayback) from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity. The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The…
Slayback Pharma LLC announced the appointment of Dr. Sumitra Pillai as Vice President and the new Head of R&D. Sumitra will be based out of Slayback’s Hyderabad, India office. Prior to joining Slayback, Sumitra was the Vice President of Research and Development at Dr. Reddy’s Laboratories where she was instrumental in successful development of numerous…
Slayback Pharma LLC has announced an agreement with The Everstone Group (“Everstone”) to invest up to US$50 million in Series B funding. The new capital will be used to expand and accelerate further Slayback’s already rich and differentiated pipeline of complex generic and specialty pharmaceutical products. In addition to the investment, Everstone Managing Directors Arjun…